Updated European Association of Urology guidelines reflect growing clinical evidence supporting Aquablation therapy in the surgical treatment of benign prostatic hyperplasiaSAN JOSE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) today highlighted the latest update to the European Association of Urology (EAU) Guidelines for male lower urinary tract symptoms (LUTS), which include an upgrade of Aquablation therapy to a strong recommendation as a surgical treatment option for me ...

PRCT: GUIDED $325.5M, HID PRICING HEADWIND -- LEVI & KORSINSKY, LLP INVESTIGATES Accessibility StatementSkip NavigationProcept BioRobotics set aggressive revenue targets while a internal pricing change was already undercutting realized salesNEW YORK, March 18, 2026 /PRNewswire/ -- Procept BioRobotics (NASDAQ: PRCT) guided investors toward $325.5 million in full-year 2025 revenue -- representing 45% growth -- then delivered $308.1 million, a $17.4 million shortfall that sent shares down more than 15%. Shareh ...

Core Insights - PROCEPT BioRobotics Corporation is under investigation for potential violations of federal securities laws, as announced by Levi & Korsinsky [1] Financial Performance - In the Q3 2025 earnings call, CFO Kevin Waters reaffirmed a revenue target of $325.5 million and maintained average selling prices for handpieces at approximately $3,200 [2] - The company implemented a pricing-discipline initiative that eliminated bulk-purchase discounts, which directly reduced realized average selling prices on its core product line [2] - Actual revenue for Q4 2025 fell short by $17.4 million compared to the guidance, and the FY 2026 revenue guidance of $410 million to $430 million was also below analyst consensus, leading to a 15% drop in stock value in a single session [3]

SAN JOSE, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT), today announced the international expansion of the HYDROS Robotic System, the company’s next-generation platform for delivering Aquablation therapy to treat benign prostatic hyperplasia (BPH). HYDROS is the first AI-enabled robotic platform designed specifically for the treatment of BPH with Aquablation therapy. Leveraging AI-interpreted, real-time ultrasound imaging and advanced image-guided treatment planning, the sys ...

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of PROCEPT BioRobotics Corporation ("Procept†or the "Company†) (NASDAQ: PRCT) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON PROCEPT BIOROBOTICS CORPORATION (PRCT) CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR. ...

Core Viewpoint - The Law Offices of Frank R. Cruz is investigating PROCEPT BioRobotics Corporation for potential violations of federal securities laws on behalf of investors who may have incurred losses [1] Group 1 - The investigation is focused on the possible legal issues surrounding Procept BioRobotics Corporation [1] - Investors who lost money on Procept BioRobotics Corporation are encouraged to inquire about pursuing a claim to recover their losses [1]

Core Insights - PROCEPT BioRobotics Corporation is under investigation for potential violations of federal securities laws, as announced by Levi & Korsinsky [1] Financial Performance - In Q3 2025 earnings call, the CFO reaffirmed a revenue target of $325.5 million and maintained average selling prices for handpieces at approximately $3,200 [2] - The company implemented a pricing-discipline initiative that eliminated bulk-purchase discounts, which directly reduced realized average selling prices on its core product line [2] - Actual revenue for Q4 2025 fell short by $17.4 million compared to the guidance, and FY 2026 guidance of $410 million to $430 million was below analyst consensus, leading to a 15% drop in stock value in a single session [3]

Core Viewpoint - The Schall Law Firm is investigating claims against PROCEPT BioRobotics Corporation for potential violations of securities laws due to misleading statements and undisclosed information affecting investors [1][2]. Group 1: Investigation Details - The investigation centers on whether PROCEPT BioRobotics issued false or misleading statements and failed to disclose critical information to investors [2]. - The company reported Q4 2025 financial results on February 25, 2026, revealing quarterly revenue significantly below analyst expectations and a substantial cut in full-year revenue guidance [2]. - The decline in performance was attributed to disruptions from a realignment and the removal of bulk-purchase discounts, leading to a more than 15.1% drop in share price the following day [2]. Group 2: Shareholder Information - Shareholders who experienced losses are encouraged to participate in the investigation and can contact the Schall Law Firm for a free discussion of their rights [3]. - The Schall Law Firm specializes in securities class action lawsuits and represents investors globally [3].

PresentationJoshua JenningsTD Cowen, Research Division [Audio Gap] devices research team, and we are in the last session of the first morning of the 46th Annual TD Cowen Healthcare Conference. And we are fortunate to have executives from PROCEPT BioRobotics CEO, Larry Wood, to my right, your left; and CFO, Kevin Waters. Gentlemen, thanks for joining us today. It was a busy week last week for you guys at earnings and you had Investor Day, and you guys laid out a lot of -- gave provided a lot of intel on four ...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PROCEPT BioRobotics Corporation - PRCT Accessibility Statement Skip NavigationNEW YORK, March 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PROCEPT BioRobotics Corporation ("Procept" or the "Company") (NASDAQ: PRCT). Such investors are advised to contact Danielle Peyton at [[email protected]] or 646-581-9980, ext. 7980.The investigation concerns whether Procept and certain of its office ...